Skip to main content
Vai all'homepage della Commissione europea (si apre in una nuova finestra)
italiano it
CORDIS - Risultati della ricerca dell’UE
CORDIS

European Novel Drug research to Address Microbial infections and drug Resistance

Descrizione del progetto

Nuove terapie per le infezioni batteriche croniche e resistenti ai farmaci

Stiamo esaurendo i trattamenti per le infezioni batteriche e il divario è maggiore nei paesi in via di sviluppo. L’Organizzazione mondiale della sanità ha avvertito che l’attuale scoperta di farmaci spesso ignora le esigenze dei paesi a basso reddito, il che non fa che aggravare la crisi globale della resistenza. Il progetto END2AMR, finanziato dall’UE, mira a sviluppare nuove terapie e tecnologie di somministrazione per le infezioni batteriche, bersagliando ceppi cronici e resistenti ai farmaci. Il progetto convaliderà i trattamenti e porterà una terapia a lunga durata d’azione allo stato preclinico. Inoltre, stabilirà percorsi per la scoperta di farmaci antibatterici e rafforzerà l’ecosistema europeo dell’innovazione sanitaria.

Obiettivo

Antimicrobial-resistant and persistent bacterial infections represent major global healthcare challenges, imposing substantial costs and highlighting the urgent need for new and more effective treatment options. The World Health Organization and other international bodies have identified critical gaps in the current antibacterial drug discovery pipeline, which relies heavily on similar mechanisms of action and fails to address the needs of low- and middle-income countries. The rapid emergence of bacterial resistance, coupled with a lack of globally applicable therapeutics, continues to exacerbate the antimicrobial resistance (AMR) crisis.

The European Novel Drug Research to Address Microbial Infections and Drug Resistance (END2AMR) consortium aims to tackle these challenges by developing innovative therapeutic modalities and delivery technologies that can overcome current treatment limitations. END2AMR brings together a multidisciplinary public–private partnership comprising pharmaceutical, biotechnology, and academic expertise to advance a diverse portfolio of novel antibacterial modalities and delivery technologies. These will be applied independently or in combination to improve patient outcomes, using specific bacterial pathogen case studies as a basis for broader translational impact. The case studies targeting specific bacterial pathogens will serve as exemplars to extend these approaches to other infectious diseases.

Main Objectives:
• Advance and validate innovative strategies to treat chronic and drug-resistant bacterial infections, with particular emphasis on Gram-negative bacteria and mycobacteria.
• Develop a versatile toolkit to enable the creation, optimization, and translation of next-generation antibacterial treatments.

Key Deliverables:
• Demonstrate proof of concept for at least three new antibacterial modalities and/or delivery technologies addressing infections currently lacking effective therapies.
• Progress at least one long-acting therapeutic to preclinical candidate status.

Long-Term Impact:
END2AMR will establish robust pathways for antibacterial drug discovery and development, including Target Product Profiles for novel modalities and delivery technologies. The project will also create a framework to support the translation and exploitation of innovative approaches generated through its activities. Ultimately, END2AMR will strengthen the European health innovation ecosystem, enhancing preparedness, resilience, and global leadership in addressing chronic bacterial infections and antimicrobial resistance through both traditional and pioneering approaches.

Acknowledgement
END2AMR is supported by the Innovative Health Initiative Joint Undertaking (IHI JU). The JU receives support from the European Union’s Horizon Europe research and innovation programme and COCIR, EFPIA, Europa Bio, MedTech Europe, and Vaccines Europe.

Campo scientifico (EuroSciVoc)

Parole chiave

Programma(i)

Argomento(i)

Meccanismo di finanziamento

HORIZON-JU-RIA - HORIZON JU Research and Innovation Actions

Vedi tutti i progetti finanziati nell’ambito di questo schema di finanziamento

Invito a presentare proposte

(si apre in una nuova finestra) HORIZON-JU-IHI-2025-09-single-stage

Vedi tutti i progetti finanziati nell’ambito del bando

Coordinatore

STICHTING LYGATURE
Contributo netto dell'UE
€ 1 140 000,00
Indirizzo
JAARBEURSPLEIN 6
3521 AL Utrecht
Paesi Bassi
PMI
Sì
Tipo di attività
Research Organisations
Collegamenti
Costo totale
€ 1 140 000,00

Partecipanti (11)

Partner (1)